Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis-Reference-Cited by-同舟云学术

Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis

Published:2020-12 Issue:12 Volume:20 Page:e961-e985
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Narayan Rupa^ORCID,Galligan Derek,Lazar Ann A.,Kim Sarah^ORCID,Fong Richard,Tan Marisela,Lo Mimi,Arora Shagun,Shah Nina,Wong Sandy W.,Martin Thomas,Wolf Jeffrey

Funder

Multiple Myeloma Research Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference19 articles.

1. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management;Rajkumar;Am J Hematol,2016

2. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma;Griffin;Cancer,2015

3. Phase I study of escalating doses of carfilzomib with hyper-CVAD in patients with newly diagnosed acute lymphoblastic leukemia/lymphoma;Fisch;Blood,2019

4. Modified hyperCVAD versus bortezomib-hyperCAD in patients with relapsed/refractory multiple myeloma;Saraceni;Clin Lymphoma Myeloma Leuk,2018

5. Retrospective review of the use of high-dose cyclophosphamide, bortezomib, doxorubicin, and dexamethasone for the treatment of multiple myeloma and plasma cell leukemia;Tabchi;Clin Lymphoma Myeloma Leuk,2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization;Transplantation and Cellular Therapy;2024-08

2. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma;Blood Advances;2024-04-29

3. Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma;Transplantation and Cellular Therapy;2023-08

4. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis;Clinical Lymphoma Myeloma and Leukemia;2023-04

5. Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2021-12